Industry Overview

Germany prostate cancer diagnosis & treatment market was valued at $915.6 million in 2025 and is projected to reach $2,232.1 million by 2035, growing at a CAGR of 9.4% during the forecast period (2026-2035). The market is growing due to the increasing incidence of prostate cancer, particularly among the aging male population. Rising awareness regarding early screening through prostate-specific antigen testing and digital rectal examination is contributing to higher diagnosis rates. Continuous advancements in diagnostic technologies and imaging accuracy are improving early detection and risk stratification. Expanding availability of advanced therapeutic options, including immunotherapy and targeted therapy, is enhancing treatment outcomes and patient survival. In addition, supportive reimbursement frameworks and strengthening oncology infrastructure across emerging and developed economies are reinforcing sustained market expansion.

Market Dynamics

Rising Disease Burden and Expanding Diagnostic Adoption

The rising incidence of prostate cancer, particularly among men above 60 years of age, remains a primary growth driver for the prostate cancer diagnosis and treatment market. Demographic shifts toward an aging population are directly increasing the patient pool requiring routine screening, confirmatory diagnostics, and long-term therapeutic management. Clinical guidelines in several countries recommend regular prostate-specific antigen testing and digital rectal examination for high-risk groups, supporting consistent diagnostic volumes. Improvements in laboratory accuracy, biomarker validation, and imaging integration are strengthening early-stage detection rates. Earlier diagnosis is leading to higher treatment initiation, thereby sustaining demand across hormonal therapy, radiation therapy, chemotherapy, immunotherapy, and targeted therapy segments.

Advancements in Therapeutic Innovation and Clinical Infrastructure

Continuous advancement in treatment innovation and precision oncology represents another major driver for market expansion. Pharmaceutical companies are expanding pipelines focused on next-generation hormonal agents, radioligand therapies, and immune-based approaches designed to improve survival outcomes in advanced and metastatic cases. Regulatory approvals for novel targeted therapies are broadening the available treatment landscape and encouraging earlier adoption in clinical practice. Expansion of specialized oncology centers and improved access to reimbursement in key healthcare systems are increasing therapy uptake. Growing clinical research activity and participation in oncology trials are accelerating the introduction of differentiated therapeutic options, reinforcing sustained market growth.

Market Segmentation

• Based on diagnostic technique, the market is segmented into prostate-specific antigen test and digital rectal exam.
• Based on therapy, the market is segmented into hormonal therapy, chemotherapy, immunotherapy, radiation therapy, and targeted therapy.

PSA Screening Sustaining Diagnostic Demand

Prostate-specific antigen (PSA) testing continues to represent the most widely used diagnostic sub-segment within Germany’s prostate cancer detection landscape. The high incidence of the disease, with more than 70,000 men diagnosed annually in the country, has sustained the need for routine screening and early diagnostic evaluation. Germany’s advanced laboratory infrastructure and established cancer screening programs have supported consistent testing volumes across hospitals and diagnostic laboratories. Diagnostic technology providers such as Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers supply automated immunoassay systems widely used for PSA analysis. Increasing awareness among aging male populations and regular health check programs are reinforcing screening participation. Recent developments include improved biomarker panels and digital pathology integration aimed at refining risk stratification and reducing unnecessary biopsies.

Radioligand Therapy Transforming Advanced Treatment

PSMA-targeted radioligand therapy has emerged as one of the fastest advancing treatment approaches for metastatic prostate cancer in Germany. The therapy combines targeted molecules with radioactive isotopes such as Lutetium-177 to selectively destroy cancer cells while minimizing damage to surrounding tissues. Clinical adoption has expanded rapidly, with the number of radioligand therapy procedures rising from around 1,026 treatments in 2016 to more than 3,300 procedures in 2020 across German nuclear medicine centers. Major participants including Bayer AG, Novartis, Siemens Healthineers, and Telix Pharmaceuticals are actively investing in radiopharmaceutical research and clinical collaborations. Current trends show growing use of theranostics, where PSMA-PET imaging is combined with radioligand therapy to guide patient selection and improve treatment precision.

Market Players Outlook

The major companies operating in the Germany prostate cancer diagnostic and therapeutic market include Bayer AG, Johnson & Johnson, Novartis AG, Pfizer Inc., Roche Holding AG, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In June 2025, the Telix Pharmaceuticals PSMA-PET imaging agent Illuccix has received marketing authorization in Germany. This radiopharmaceutical enables highly accurate PET imaging of prostate-specific membrane antigen (PSMA)-positive prostate cancer lesions, supporting better staging and disease monitoring across multiple clinical settings. Distribution in Germany is supported by a local imaging partner network.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the Germany prostate cancer diagnostic and therapeutic market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.